Adial Pharmaceuticals, Inc. (ADIL) |
|
0.4092 -0.006 (-1.4%)
|
03-22 12:06 |
|
Open: |
0.4125 |
Pre. Close: |
0.415 |
|
High:
|
0.435 |
Low:
|
0.4 |
|
Volume:
|
47,262 |
Market Cap:
|
12(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 11:44:10 AM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 0.57 One year: 0.7 |
| Support: |
Support1: 0.31 Support2: 0.25 |
| Resistance: |
Resistance1: 0.48 Resistance2: 0.6 |
| Pivot: |
0.43 |
| Moving Average: |
MA(5): 0.41  MA(20): 0.44
MA(100): 0.33 MA(250): 0.74 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 36 %D(3): 35.5 |
| RSI: |
RSI(14): 48.2 |
| 52-week: |
High: 2.26 Low: 0.2 |
| Average Vol(K): |
3-Month: 768 (K) 10-Days: 610 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ADIL ] has closed above bottom band by 36.0%. Bollinger Bands are 48.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.46 - 0.46 |
0.46 - 0.46 |
|
Low:
|
0.4 - 0.4 |
0.4 - 0.4 |
|
Close:
|
0.41 - 0.42 |
0.42 - 0.42 |
|
Company Description |
|
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. |
Headline News |
Tue, 21 Mar 2023
Adial Pharmaceuticals (ADIL) Engages The Keswick Group to ... - StreetInsider.com
Wed, 08 Mar 2023
Why Rigel Pharmaceuticals Shares Are Trading Higher By Over 30 ... - Investing.com UK
Wed, 08 Mar 2023
Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th - Yahoo Finance
Tue, 07 Mar 2023
Why Rivian Automotive Shares Are Trading Lower By Over 10 ... - Investing.com UK
Tue, 07 Mar 2023
Meta's stock up on report of more layoffs, and WeightWatchers telehealth deal gives it access to promising obesity drug market - MarketWatch
Mon, 06 Mar 2023
Is it Time to Dump Adial Pharmaceuticals Inc (ADIL) Stock After it Has Fallen 6.67% in a Week? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
29 (M) |
| Shares Float |
23 (M) |
|
% Held by Insiders
|
46.5 (%) |
|
% Held by Institutions
|
19.1 (%) |
|
Shares Short
|
382 (K) |
|
Shares Short P.Month
|
134 (K) |
Stock Financials |
|
EPS
|
-0.65 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.2 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-99.5 |
|
Return on Equity (ttm)
|
-249 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.51 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-12 (M) |
|
Levered Free Cash Flow
|
-6 (M) |
Stock Valuations |
|
PE Ratio
|
-0.63 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.04 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.99 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
